A dual-site dietary intervention study to integrate dietary assessment methods

ISRCTN ISRCTN13562899
DOI https://doi.org/10.1186/ISRCTN13562899
IRAS number 321986
Secondary identifying numbers 22HH8106, IRAS 321986, CPMS 58355
Submission date
03/08/2023
Registration date
01/09/2023
Last edited
04/10/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Diet has a huge impact on the health and well-being of individuals and is a major contributor to the development of a range of chronic health conditions, such as diabetes, cardiovascular diseases, and many cancers. Many countries are facing rising levels of obesity and diet-related disease due to changes in dietary choices and eating behaviour, as well as more sedentary lifestyles. The robustness and impact of strategies aimed at addressing nutrition-related problems are consistently undermined by misreporting of dietary intake caused by our lack of an accurate tool to assess and monitor dietary intakes. Self-reporting tools used traditionally to capture information about diet include Food Frequency Questionnaires (FFQs), 24-hour dietary recalls and food diaries. These tools struggle to categorise and represent accurately dietary intake and often involve costly expert researcher support, a substantial burden to study/survey participants and are subject to poor compliance, dietary change, and significant reporting bias. To improve dietary reporting, the researchers will bring together three additional technologies which have shown promise in improving accurate reporting of dietary intake. These are urine biomarkers, capillary blood biomarkers and wearable micro cameras. The overall aim of this study is to improve the accuracy of dietary reporting by combining all these tools.

Who can participate?
Healthy volunteers aged 18 to 70 and have a Body Mass Index (BMI) between 20-30 kg/m2

What does the study involve?
Participants will attend to undergo two 4-day dietary interventions and return the samples on the 5th day with a minimum of 1 week between both visits, with the administration of a healthy diet intervention compliant with current dietary healthy guidelines and an unhealthy diet intervention. Diets will consist of a 2-day repeating menu delivered twice over the 4 days.
Participants will be given a micro camera to wear for the duration of the two, four-day study periods. The camera will automatically capture images of everything that a participant eats and drinks at regular intervals (e.g., one image per second) and must be worn continuously during the study period, including when at home. Participants will also collect first morning urine and evening urine samples on all study days plus a first morning urine on day 5. These samples will be returned to the research facility each day the participant attends. In addition to the urine samples, participants will also collect a capillary blood sample. These blood samples will be collected by the participant on days 1, 2 and 4 of each study period. The blood collection uses a device called ‘OneDraw’ and involves attaching the devices to your upper arm where it then collects 3 small drops of blood. Participants will collect these samples while at the research centre, and a researcher will be present if the participant requires any assistance with the sample collection.
Participants will also use two online self-reporting dietary assessment tools called eNutri and Intake24. These online tools are simple to use and can be used on any type of device (laptop, tablet, smartphone) which has a web browser. Intake24 records a person’s diet from the previous 24 hours, so participants will complete this a total of eight times during the study (four times for each study period). eNutri features a graphical FFQ that asks participants about their dietary intake over a longer period. Participants will record their dietary intake using eNutri at the start of the study to capture their habitual diet and again at the end of each study period to capture foods/drinks consumed in the test diets.
Participants will be asked to complete a short questionnaire on how easy/difficult they found completing the five different dietary assessment methods

What are the possible benefits and risks of participating?
Participants will receive £400 upon completion of the study to reimburse them for the time they have taken to attend study visits.

Where is the study run from?
1. Imperial College London (UK)
2. Hugh Sinclair Unit for Human Nutrition at the University of Reading (UK)

When is the study starting and how long is it expected to run for?
September 2022 to October 2024

Who is funding the study?
1. Medical Research Council (MRC) (UK)
2. Biotechnology and Biological Sciences Research Council (BBSRC) (UK)

Who is the main contact?
1. Dr Katerina Petropoulou, katerina.petropoulou12@imperial.ac.uk
2. Dr Michelle Weech, m.weech@reading.ac.uk

Study website

Contact information

Prof Gary Frost
Principal Investigator

Nutrition Research Section
Hammersmith Hospital Campus, Imperial College
6th Floor, Commonwealth Building
Du Cane Road
London
W12 0NN
United Kingdom

Phone +44 (0)20 7594 0959
Email g.frost@imperial.ac.uk
Prof Julie Lovegrove
Principal Investigator

Hugh Sinclair Unit of Human Nutrition
Department of Food and Nutritional Sciences
University of Reading
Whiteknights
PO Box 226
Reading
RG6 6DZ
United Kingdom

Phone +44 (0)118 378 6418
Email j.a.lovegrove@reading.ac.uk
Prof John Draper
Principal Investigator

Aberystwyth University
Department of Life Sciences
Edward Llwyd Building
Penglais
Aberystwyth
SY23 3DA
United Kingdom

Phone +44 (0)1970 622789
Email jhd@aber.ac.uk
Dr Amanda Lloyd
Scientific

Aberystwyth University
Department of Life Sciences
Edward Llwyd Building
Penglais
Aberystwyth
SY23 3DA
United Kingdom

Phone +44 (0)1970 622789
Email abl@aber.ac.uk
Dr Thomas Wilson
Scientific

Aberystwyth University
Department of Life Sciences
Edward Llwyd Building
Penglais
Aberystwyth
SY23 3RB
United Kingdom

Phone +44 (0)1970 622789
Email tpw2@aber.ac.uk
Dr Manfred Beckmann
Scientific

Aberystwyth University
Department of Life Sciences
Edward Llwyd Building
Penglais
Aberystwyth
SY23 3DA
United Kingdom

Phone +44 (0)1970 622340
Email meb@aber.ac.uk
Dr Rosalind Fallaize
Scientific

Hugh Sinclair Unit of Human Nutrition
Department of Food and Nutritional Sciences
University of Reading
Whiteknights
PO Box 226
Reading
RG6 6DZ
United Kingdom

Phone +44 (0)118 378 6394
Email r.fallaize@reading.ac.uk
Dr Albert Koulman
Scientific

University of Cambridge
Pathology building Level 4
Addenbrooke’s Hospital
Cambridge
CB2 0QQ
United Kingdom

Phone +44 (0)1223 763202
Email ak675@cam.ac.uk
Dr Michelle Weech
Public

Hugh Sinclair Unit of Human Nutrition
Department of Food and Nutritional Sciences
University of Reading
Whiteknights
PO Box 226
Reading
RG6 6DZ
United Kingdom

Phone +44 (0)118 378 5360
Email m.weech@reading.ac.uk
Dr Katerina Petropoulou
Public

Nutrition Research Section
Hammersmith Hospital Campus, Imperial College
6th Floor, Commonwealth Building
Du Cane Road
London
W12 0NN
United Kingdom

Phone +44 (0)7428 732 523
Email katerina.petropoulou12@imperial.ac.uk

Study information

Study designRandomized cross over trial
Primary study designInterventional
Secondary study designRandomised cross over trial
Study setting(s)Home, University/medical school/dental school
Study typeScreening
Participant information sheet 44059_PIS_v2.0_07June2023.pdf
Scientific titleData-driven integration of emerging technologies to generate a Standardized and Objective Dietary Intake Assessment Tool – Study 1
Study acronymSODIAT
Study objectivesIntegration of multiple dietary assessment technologies (wearable micro cameras, spot urine samples and capillary blood samples) can increase the accuracy of the measurement of nutritional intake during a controlled dietary intervention.
Ethics approval(s)

Approved 01/06/2023, Camden & Kings Cross Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, United Kingdom; +44 (0)207 104 8089; CamdenandKingsCross.REC@hra.nhs.uk), ref: 23/LO/0437

Health condition(s) or problem(s) studiedNutritional intake
InterventionThe study visits will take place at the NIHR/Imperial Clinical Research Facility at Hammersmith Hospital or the Hugh Sinclair Unit of Human Nutrition at the University of Reading and will include two 4-day study periods as follows: Study period 1 will involve 4 full day visits and another visit on the 5th day to return samples and study equipment. Between the two-study period, there will be a minimum of a 1-week gap. Study period 2 will involve the same number of visits as study period 1.

For the respective study period, participants will be asked to attend the research unit at 8 am every morning of the eight study days, following a 12-hour overnight fast (not consuming any food or drink, except water) and remain in the unit until 6 pm. Blood pressure, height and body weight will be measured when they arrive on the first day of each study period.

Simple randomisation will be used to assign the order in which participants receive the intervention menus. In randomised order, participants will receive a test diet during each study period that has a different level of compliance with UK healthy eating guidelines. Diet 1 is designed to be far from meeting healthy eating dietary guidelines (e.g., high in saturated fat, free sugars, and salt and low in fruit, vegetables, and fibre), whereas Diet 2 is compliant with healthy eating dietary guidelines (e.g., high in fibre, fruits and vegetables, and low in saturated fat, free sugars and salt).

Participants will be served meals and snacks throughout the eight study days (8 am – 6 pm) according to the diet they have been randomly assigned during each study period. Diets will consist of a 2-day repeating menu (e.g., menu 1 on days 1 and 3, and menu 2 on days 2 and 4). At 6 pm of the four study days, they will return home with a snack and bottled water to be consumed in the evening. They will be instructed not to eat or drink anything, except for the evening snack and drinks provided between each 4-day study period.
Intervention typeOther
Primary outcome measureThe accuracy of dietary reporting will be measured at the end of each intervention week using dietary data collected from wearable micro cameras, spot urine samples, capillary blood samples, and self-report dietary recalls. Total daily consumption (grams per day) will be reported by wearable micro cameras and self-report dietary recalls. Liquid chromatography-mass spectrometry (LC-MS) will measure biomarkers of dietary components in spot urine samples and capillary blood samples and daily dietary intake will be reported using µg/ml concentrations of dietary exposure biomarkers.
Secondary outcome measures1. Creation of a multiplatform model of dietary intake using g/day measured from wearable micro-cameras and self-report dietary recalls, and µg/ml of dietary exposure biomarkers from spot urine samples and capillary blood samples at the end of the study
2. Design a dietary intake study informed by the results of the dietary intake study protocol in a free-living population at the end of the study

Overall study start date01/09/2022
Completion date01/10/2024

Eligibility

Participant type(s)Healthy volunteer
Age groupAdult
Lower age limit18 Years
Upper age limit70 Years
SexBoth
Target number of participants30
Key inclusion criteria1. Aged 18 – 70 years
2. Body Mass Index (BMI) 20-30 kg/m²
Key exclusion criteria1. Have been involved in any other study during the previous 12 weeks, are not able to commit to the study (e.g., travel commitments) or are unwilling to collect urine and blood samples and wear the micro-camera
2. Had a weight change of more than 3kg in the preceding 3 months or are currently following a weight-loss diet
3. Have excess alcohol intake (more than 21 units per week) (e.g., a medium glass of wine = 2.3 units)
4. Are unwilling to abstain from drinking alcohol and avoiding strenuous exercise during the two 5-day test periods
5. Are unwilling to follow the study menus (e.g., dislike of food items, following a restrictive/specialised diet or receiving specialised dietary advice for a medical condition); participants will not be permitted to eat/drink anything else during the two 5-day test periods
6. Are not able to eat fish and/or meat (e.g., are vegan or vegetarian)
7. Have an allergy/intolerance to any of the food items in the menu
8. Have taken any dietary supplements in the last 3 months (e.g., multivitamins, fish oils)
9. Are pregnant or lactating
10. Currently, suffer from any of the following: eating disorders, diabetes, cancer, gastrointestinal disorders (e.g., inflammatory bowel disease or irritable bowel syndrome), kidney disease, liver disease, pancreatitis, HIV or AIDS or any other chronic illness
11. Are taking any of the following medications: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin, or thyroid hormones
12. Use illicit substances
13. Have been diagnosed with dementia or other conditions affecting memory
14. Have difficulty using laptops/tablets (e.g., cannot use these devices without assistance, are blind or have other conditions affecting sight, or have physical disabilities/conditions that affect your ability to press buttons)
15. Cannot read and understand English
Date of first enrolment01/09/2023
Date of final enrolment01/08/2024

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centres

NIHR Imperial CRF
Imperial Centre for Translational and Experimental Medicine
Hammersmith Hospital
London
W12 0HS
United Kingdom
Hugh Sinclair Unit of Human Nutrition
Harry Nursten Building
University of Reading
Whiteknights
Reading
RG6 6DZ
United Kingdom

Sponsor information

Imperial College London
University/education

Research Governance and Integrity Team
Academic Health Science Centre
Imperial College London and
Imperial College Healthcare NHS Trust
Room 221, Medical School Building
St Mary’s Hospital
Praed Street
London
W2 1NY
England
United Kingdom

Phone +44 (0)20 7594 8081
Email r.ezra@imperial.ac.uk
Website https://www.ic.ac.uk/clinicalresearchgovernanceoffice
ROR logo "ROR" https://ror.org/041kmwe10

Funders

Funder type

Research council

Medical Research Council
Government organisation / National government
Alternative name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC
Location
United Kingdom
Biotechnology and Biological Sciences Research Council
Government organisation / National government
Alternative name(s)
UKRI - Biotechnology And Biological Sciences Research Council, BBSRC UK, BBSRC
Location
United Kingdom

Results and Publications

Intention to publish date01/02/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryStored in publicly available repository
Publication and dissemination planThe results of this study will also be presented at medical meetings and research conferences and published in scientific journals 6 months following the end of the study. They will also be used by research students who are associated with this project in work that will contribute to their degree or other qualification. The researchers also hope to publish the results in the press and media.
IPD sharing planAnonymised data will be made publicly available through deposition in online public repositories upon dissemination and publication of study results. Raw data from mass spectrometry analysis of collected biofluids (urine and blood) will be deposited in the MetaboLights repository (
https://www.ebi.ac.uk/metabolights/) and all experimentally derived data will be deposited in the Zenodo repository (https://zenodo.org/) at the time of publication.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet version 2.0 07/06/2023 17/08/2023 No Yes

Additional files

44059_PIS_v2.0_07June2023.pdf

Editorial Notes

04/10/2023: Internal review.
17/08/2023: Trial's existence confirmed by the Health Research Authority (HRA) (UK).